- 同花顺特色产品
- 〈高级诊股〉 全方位深度分析，提供明确投资建议
- 短期趋势：
该股进入多头行情中，股价短线上涨概率较大。
- 中期趋势：
正处于反弹阶段。
- 长期趋势：
已有417家主力机构披露2026-06-30报告期持股数据，持仓量总计1.70亿股，占流通A股31.67%
- 波段诊断：
-
技术面诊股
诊断结果：5.9技术面打败了46%的股票
技术面评分前10的股票
近期的平均成本为58.93元。空头行情中，目前正处于反弹阶段，投资者可适当关注。
平均成本
近期的平均成本为58.93元。
[{"text":"\u5e73\u5747\u6210\u672c","value":"58.93","date":1794384368,"color":"0x9f0ba1"}]
市场表现
过去10个交易日，该股走势跑赢大盘，接近行业平均水平。
[{"date":"2026.11.12","stock":"1.48","trade":"-0.89","ind":"-1.68"},{"date":"2026.11.11","stock":"-0.72","trade":"0.22","ind":"1.32"},{"date":"2026.11.10","stock":"0.10","trade":"0.72","ind":"0.86"},{"date":"2026.11.09","stock":"-0.85","trade":"-0.46","ind":"-0.27"},{"date":"2026.11.06","stock":"-0.25","trade":"-1.77","ind":"-2.57"},{"date":"2026.11.05","stock":"0.02","trade":"2.29","ind":"1.19"},{"date":"2026.11.04","stock":"5.02","trade":"2.96","ind":"4.22"},{"date":"2026.11.03","stock":"-1.90","trade":"-0.88","ind":"-1.21"},{"date":"2026.11.02","stock":"4.47","trade":"1.70","ind":"1.63"},{"date":"2026.10.30","stock":"-5.40","trade":"-1.05","ind":"-2.73"},{"date":"2026.10.29","stock":"0.35","trade":"-1.88","ind":"-2.92"},{"date":"2026.10.28","stock":"1.98","trade":"1.46","ind":"2.02"},{"date":"2026.10.27","stock":"-3.53","trade":"-3.85","ind":"-2.50"},{"date":"2026.10.26","stock":"-2.89","trade":"0.14","ind":"-1.19"},{"date":"2026.10.23","stock":"2.47","trade":"1.64","ind":"2.79"},{"date":"2026.10.22","stock":"-2.17","trade":"-3.34","ind":"-2.96"},{"date":"2026.10.21","stock":"1.17","trade":"0.13","ind":"-0.82"},{"date":"2026.10.20","stock":"4.34","trade":"1.00","ind":"-0.14"},{"date":"2026.10.19","stock":"0.60","trade":"-1.42","ind":"0.13"},{"date":"2026.10.16","stock":"1.39","trade":"-0.03","ind":"-0.12"},{"date":"2026.10.15","stock":"-3.58","trade":"-1.39","ind":"-2.43"}]
海思科,深证成指,化学制药指数
压力支撑
该股压力位为58.44元，支撑位为57.15元。
[{"text":"\u538b\u529b\u4f4d","value":"58.44","date":1794412800,"color":"0x9f0ba1"},{"text":"\u652f\u6491\u4f4d","value":"57.15","date":1794412800,"color":"0x0b52a1"}]
多空趋势
空头行情中，目前正处于反弹阶段，投资者可适当关注。
macd
kdj
boll
asi
bias
rsi
wr
vr
资金面诊股
诊断结果：6.2资金面打败了93%的股票
主力控盘前10的股票
行业资金
化学制药行业， 近5日资金流出较多，不建议投资者关注该行业的个股。
更新时间：11月12日 20:30
| 机构今日流向(万元) | -1354.47 | 机构5日流向(万元) | -6098.40 |
| 机构10日流向(万元) | -1575.32 | 机构20日流向(万元) | -8166.34 |
机构持仓
2026-06-30 与 2025-12-31 相比，主力机构持仓量减少402.46万股，其中基金净减仓13家，主力净增仓167家，暂未发现中长期投资价值。
截止2026-06-30，共417家主力机构（基金416家，一般法人1家），持仓量总计17006.09万股，占流通A股31.67%
其中，基金持仓与2025-12-31相比：
增仓：70家 ，增持 1974.24万股
减仓：83家 ，减持 2299.71万股
新出现在主力名单中：253家 ，持有1442.19万股
从主力名单中消失：86家 ，原持有1203.35万股
其中，基金持仓与2025-12-31相比：
增仓：70家 ，增持 1974.24万股
减仓：83家 ，减持 2299.71万股
新出现在主力名单中：253家 ，持有1442.19万股
从主力名单中消失：86家 ，原持有1203.35万股
消息面诊股
诊断结果：7.2消息面打败了97%的股票
今日有利好新闻的公司
近期利好消息较多且有重大利好，消息面发出积极信号。
更多>>个股资讯
- 国产首个口服IL-23启动III期临床
2026-11-12 - 海思科：11月11日获融资买入1506.13万元
2026-11-12 - 海思科：11月10日持仓该股ETF资金净流入112
2026-11-11 - 海思科：11月10日获融资买入769.30万元
2026-11-11 - 三季报收官后，再看中国创新药企成色
2026-11-11 - 36个药品燃爆千亿市场！石药夺“双料冠军”，海思科
2026-11-11 - 海思科：11月9日获融资买入713.48万元
2026-11-10 - 海思科：11月6日持仓该股ETF资金净流入23.1
2026-11-09 - 海思科：11月6日获融资买入1078.99万元
2026-11-09 - 解码《医药工业发展“十五五”规划》（上）
2026-11-06
消息列表
| 利好 | 分红转增 | 10派5.26元(含税) | 2026-10-28 |
| 重大利好 | 业绩预告 | 业绩大幅上升 | 2026-10-21 |
| 一般消息 | 股东大会 | 临时股东大会 | 2026-09-18 |
| 一般消息 | 募资投向 | 2026-09-17 | |
| 一般消息 | 重大事项 | 公司股东股份解押 | 2026-09-09 |
| 利好 | 分红转增 | 10派5.26元(含税) | 2026-08-27 |
| 一般消息 | 募资投向 | 公司购买资产 | 2026-08-26 |
| 一般消息 | 重大事项 | 关联交易 | 2026-08-26 |
| 一般消息 | 募资投向 | 公司购买资产 | 2026-08-20 |
| 一般消息 | 重大事项 | 公司股东股份解押 | 2026-08-12 |
| 一般消息 | 高管变动 | 连续担任独立董事已满六年 | 2026-07-20 |
| 重大利好 | 业绩预告 | 业绩大幅上升 | 2026-07-09 |
| 利好 | 股票增发 | 已实施 | 2026-07-08 |
| 利好 | 重大事项 | 参股拟上市公司或非上市公司金融机构 | 2026-06-30 |
| 一般消息 | 重大事项 | 关联交易 | 2026-04-30 |
| 重大利好 | 业绩预告 | 业绩大幅上升 | 2026-04-13 |
| 利好 | 分红转增 | 10派2.67元(含税) | 2026-04-13 |
| 一般消息 | 重大事项 | 公司股东股份解押 | 2026-01-14 |
| 一般消息 | 募资投向 | 公司购买资产 | 2026-01-10 |
| 一般消息 | 重大事项 | 关联交易 | 2026-01-10 |
| 一般消息 | 重大事项 | 关联交易 | 2026-01-06 |
| 利好 | 重大事项 | 参股拟上市公司或非上市公司金融机构 | 2025-12-31 |
| 一般消息 | 重大事项 | 公司股东股份解押 | 2025-12-19 |
| 一般消息 | 重大事项 | 公司股东股份解押 | 2025-11-13 |
一年消息统计
| 所有消息 | 重大消息 | 非重大消息 | |
| 利好 | 9条 | 3条 | 6条 |
| 利空 | 0条 | 0条 | 0条 |
行业面诊股
诊断结果：7.8行业面打败了90%的股票
化学制药行业最新资金流向
近10日来该行业走势不明显，明显跑赢大盘。最近120个交易日，机构评级以增持为主，认为该行业有一定投资价值。
行业走势
近10日来该行业走势不明显，明显跑赢大盘。
[{"date":"2026.11.12","price":"-1.68","value":"-0.89"},{"date":"2026.11.11","price":"1.32","value":"0.22"},{"date":"2026.11.10","price":"0.86","value":"0.72"},{"date":"2026.11.09","price":"-0.27","value":"-0.46"},{"date":"2026.11.06","price":"-2.57","value":"-1.77"},{"date":"2026.11.05","price":"1.19","value":"2.29"},{"date":"2026.11.04","price":"4.22","value":"2.96"},{"date":"2026.11.03","price":"-1.21","value":"-0.88"},{"date":"2026.11.02","price":"1.63","value":"1.70"},{"date":"2026.10.30","price":"-2.73","value":"-1.05"},{"date":"2026.10.29","price":"-2.92","value":"-1.88"},{"date":"2026.10.28","price":"2.02","value":"1.46"},{"date":"2026.10.27","price":"-2.50","value":"-3.85"},{"date":"2026.10.26","price":"-1.19","value":"0.14"},{"date":"2026.10.23","price":"2.79","value":"1.64"},{"date":"2026.10.22","price":"-2.96","value":"-3.34"},{"date":"2026.10.21","price":"-0.82","value":"0.13"},{"date":"2026.10.20","price":"-0.14","value":"1.00"},{"date":"2026.10.19","price":"0.13","value":"-1.42"},{"date":"2026.10.16","price":"-0.12","value":"-0.03"},{"date":"2026.10.15","price":"-2.43","value":"-1.39"}]
深证成指,化学制药行业
行业排名
| 排名 | 股票名称 | 1月涨跌幅 | 5日涨跌幅 | 评分 |
|---|---|---|---|---|
| 1 | 莱美药业 | 45.51% | 15.53% | 6.2分 |
| 2 | 海正药业 | 19.43% | -3.54% | 6.1分 |
| 3 | 昂利康 | 17.28% | -8.59% | 6.0分 |
| 4 | 百济神州 | 16.92% | 4.95% | 6.4分 |
| 5 | 海创药业 | 15.93% | -7.30% | 5.2分 |
| 6 | 华纳药厂 | 13.98% | 12.86% | 5.9分 |
| 8 | 科伦药业 | 11.16% | -3.96% | 6.5分 |
| 10 | ST复华 | 10.53% | 7.94% | 5.5分 |
| 12 | 贝达药业 | 9.55% | -6.22% | 5.7分 |
| 14 | 迪哲医药 | 9.12% | -3.64% | 6.0分 |
| 16 | ST天圣 | 7.87% | -1.63% | 5.6分 |
| 18 | 威尔药业 | 7.22% | 2.36% | 6.1分 |
| 20 | 首药控股 | 6.52% | -4.90% | 5.0分 |
| 22 | 上海谊众 | 5.51% | -0.22% | 5.5分 |
| 24 | ST能特 | 4.51% | 8.51% | 6.0分 |
| 26 | 恩华药业 | 4.19% | -4.08% | 5.7分 |
| 28 | 通化金马 | 3.88% | 1.56% | 5.8分 |
| 30 | 汇宇制药 | 3.61% | -1.75% | 4.9分 |
| 32 | 华海药业 | 3.46% | -4.53% | 6.0分 |
| 34 | 奥赛康 | 3.37% | -1.56% | 6.5分 |
| 36 | 海欣股份 | 1.59% | -1.22% | 5.6分 |
| 38 | 北大医药 | 1.48% | 0.73% | 6.1分 |
| 40 | ST诺泰 | 1.15% | 2.36% | 5.5分 |
| 42 | 亿帆医药 | 0.00% | -5.43% | 5.6分 |
| 44 | 川宁生物 | 0.00% | -7.16% | 5.3分 |
| 46 | 新和成 | -0.35% | -5.03% | 5.3分 |
| 48 | 小方制药 | -0.49% | -3.05% | 5.0分 |
| 50 | 吉贝尔 | -0.76% | -1.57% | 4.3分 |
| 52 | - | -1.43% | -2.48% | 分 |
| 54 | 海普瑞 | -1.60% | -3.65% | 6.2分 |
| 56 | 永安药业 | -1.61% | -1.93% | 6.1分 |
| 58 | 艾力斯 | -1.65% | -4.30% | 5.0分 |
| 60 | 前沿生物 | -1.94% | 0.15% | 5.4分 |
| 62 | 宏源药业 | -2.49% | -4.04% | 5.6分 |
| 64 | 纳微科技 | -2.62% | -3.42% | 4.7分 |
| 66 | 诚意药业 | -2.68% | -3.54% | 4.8分 |
| 68 | - | -2.94% | -2.39% | 分 |
| 70 | 凯因科技 | -3.32% | -2.44% | 5.0分 |
| 72 | 微芯生物 | -3.51% | -1.08% | 5.5分 |
| 74 | 同和药业 | -3.67% | -2.09% | 5.7分 |
| 76 | 国药现代 | -3.93% | -3.47% | 5.0分 |
| 78 | 本立科技 | -4.26% | 1.18% | 5.6分 |
| 80 | 国邦医药 | -4.51% | -2.15% | 5.9分 |
| 82 | 康芝药业 | -4.89% | -0.61% | 5.4分 |
| 84 | 海南海药 | -5.37% | -2.17% | 5.2分 |
| 86 | 天新药业 | -5.85% | -3.42% | 4.2分 |
| 88 | 翰宇药业 | -6.11% | -7.32% | 5.9分 |
| 90 | 亚太药业 | -6.28% | 1.09% | 5.3分 |
| 92 | 花园生物 | -6.41% | -2.62% | 5.1分 |
| 94 | 易明医药 | -6.67% | 0.85% | 5.4分 |
| 96 | 复旦张江 | -6.73% | -2.62% | 4.5分 |
| 98 | 海森药业 | -6.94% | -3.07% | 4.6分 |
| 100 | 苑东生物 | -7.17% | 0.78% | 5.1分 |
| 102 | 立方制药 | -7.30% | -1.63% | 6.0分 |
| 104 | 圣诺生物 | -7.40% | -6.14% | 5.5分 |
| 106 | 力生制药 | -7.52% | -3.65% | 5.2分 |
| 108 | 莎普爱思 | -7.94% | 1.95% | 4.6分 |
| 110 | 山河药辅 | -7.99% | -1.43% | 5.4分 |
| 112 | 拓新药业 | -8.01% | -2.59% | 4.6分 |
| 114 | 福安药业 | -8.16% | -3.49% | 5.4分 |
| 116 | 哈药股份 | -8.24% | -2.07% | 5.7分 |
| 118 | 赛分科技 | -8.62% | -1.37% | 6.2分 |
| 120 | *ST集友 | -8.70% | -1.40% | 4.3分 |
| 122 | 奥翔药业 | -8.84% | -3.97% | 4.3分 |
| 124 | 亚虹医药 | -9.23% | -4.19% | 4.8分 |
| 126 | 石药景峰 | -9.41% | -7.27% | 5.2分 |
| 128 | 宣泰医药 | -9.47% | 0.24% | 4.9分 |
| 130 | 联环药业 | -9.77% | -1.97% | 6.1分 |
| 132 | - | -10.08% | 0.56% | 分 |
| 134 | 浙江医药 | -10.60% | -5.05% | 5.3分 |
| 136 | 华仁药业 | -10.67% | -1.47% | 5.4分 |
| 138 | 鲁抗医药 | -10.81% | -3.04% | 5.3分 |
| 140 | 仟源医药 | -11.11% | -1.68% | 5.3分 |
| 142 | 中哲精化 | -11.86% | 1.01% | 6.0分 |
| 144 | 赛托生物 | -12.22% | -1.05% | 4.8分 |
| 146 | 新天地 | -12.78% | -2.31% | 5.0分 |
| 148 | 润都股份 | -12.93% | -3.17% | 5.9分 |
| 150 | 神奇制药 | -13.65% | 1.07% | 5.7分 |
| 152 | 西点药业 | -16.43% | -1.71% | 5.2分 |
| 154 | 东亚药业 | -16.89% | -8.37% | 3.7分 |
| 156 | 石药创新 | -17.71% | -1.31% | 5.8分 |
| 158 | 灵康药业 | -21.79% | 0.54% | 5.0分 |
| 160 | 联亚药业 | -44.19% | -10.05% | 6.0分 |
行业评级
最近120个交易日，机构评级以增持为主，认为该行业有一定投资价值。
- 综合评级
| 研究机构 | 评级日期 | 最新评级 | 上次评级 |
| 中信证券 | 2012-09-10 | 增持 | 增持 |
| 招商证券 | 2012-09-08 | 增持 | 增持 |
| 航天证券 | 2012-09-06 | 增持 | - |
| 中银国际 | 2012-09-05 | 增持 | - |
| 齐鲁证券 | 2012-09-05 | 增持 | - |
更多>>行业资讯
- 2012-09-13亿利能源股权质押登记
- 2012-09-13太极集团修改《公司章程》
- 2012-09-13人福医药获得国家补助资金
- 2012-09-13常山药业：归还暂时用于补充流动资金的闲置募集资金
- 2012-09-13贵州百灵：公司与济南百诺医药科技开发有限公司签订技
- 2012-09-13振东制药山西省第三建筑工程公司承建山西振东泰盛制药
- 2012-09-13双成药业：战略合作框架协议进展
- 2012-09-13佛慈制药：签订推荐恢复上市、委托代办股份转让协议
- 2012-09-13昊海生科IPO资产被疑是大江股份上市募投项目
- 2012-09-13泰格医药涨势猛 业务有望快速扩张
基本面诊股
[ 截止日期：2026-09-30 ]公司经营
盈利能力：很强，居行业前列，两项指标的行业排名分别为 7/217 ， 18/217。
[{"date":"2026-09-30","value":"26.86","vol":"-3.50"},{"date":"2026-06-30","value":"18.70","vol":"-0.06"},{"date":"2026-03-31","value":"12.14","vol":"0.46"},{"date":"2025-12-31","value":"6.11","vol":"-1.74"},{"date":"2025-09-30","value":"7.00","vol":"1.57"}]
| 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|---|
| 净资产收 益率(%) |
26.86 | 18.70 | 12.14 | 6.11 | 7.00 |
| 行业(%) | -3.50 | -0.06 | 0.46 | -1.74 | 1.57 |
该指标值越高，盈利能力越强，行业排名越靠前。
[{"date":"2026-09-30","value":"80.45","vol":"49.55"},{"date":"2026-06-30","value":"80.24","vol":"49.07"},{"date":"2026-03-31","value":"81.40","vol":"50.10"},{"date":"2025-12-31","value":"71.16","vol":"49.45"},{"date":"2025-09-30","value":"73.90","vol":"49.28"}]
| 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|---|
| 销售毛利 率(%) |
80.45 | 80.24 | 81.40 | 71.16 | 73.90 |
| 行业(%) | 49.55 | 49.07 | 50.10 | 49.45 | 49.28 |
该指标值越高，盈利能力越强，行业排名越靠前。
成长能力：很强，居行业前列，两项指标的行业排名分别为 12/217 ， 12/217。
[{"date":"2026-09-30","value":"50.61","vol":"42.54"},{"date":"2026-06-30","value":"54.71","vol":"19.66"},{"date":"2026-03-31","value":"75.33","vol":"23.45"},{"date":"2025-12-31","value":"17.91","vol":"37.42"},{"date":"2025-09-30","value":"19.95","vol":"139.36"}]
| 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|---|
| 营业收入同 比增长率(%) |
50.61 | 54.71 | 75.33 | 17.91 | 19.95 |
| 行业(%) | 42.54 | 19.66 | 23.45 | 37.42 | 139.36 |
该指标值越高，成长能力越强，行业排名越靠前。
[{"date":"2026-09-30","value":"314.01","vol":"151.58"},{"date":"2026-06-30","value":"426.98","vol":"353.66"},{"date":"2026-03-31","value":"1089.85","vol":"48.30"},{"date":"2025-12-31","value":"-34.36","vol":"-23.63"},{"date":"2025-09-30","value":"-22.66","vol":"3.94"}]
| 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|---|
| 净利润同比 增长率(%) |
314.01 | 426.98 | 1089.85 | -34.36 | -22.66 |
| 行业(%) | 151.58 | 353.66 | 48.30 | -23.63 | 3.94 |
该指标值越高，成长能力越强，行业排名越靠前。
营运能力：很强，居行业前列，两项指标的行业排名分别为 7/217 ， 23/217。
[{"date":"2026-09-30","value":"0.62","vol":"0.31"},{"date":"2026-06-30","value":"0.42","vol":"0.21"},{"date":"2026-03-31","value":"0.21","vol":"0.10"},{"date":"2025-12-31","value":"0.64","vol":"0.41"},{"date":"2025-09-30","value":"0.47","vol":"0.30"}]
| 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|---|
| 总资产周 转率(次) |
0.62 | 0.42 | 0.21 | 0.64 | 0.47 |
| 行业(次) | 0.31 | 0.21 | 0.10 | 0.41 | 0.30 |
该指标值越高，营运能力越强，行业排名越靠前。
[{"date":"2026-09-30","value":"3.05","vol":"1.93"},{"date":"2026-06-30","value":"1.86","vol":"1.30"},{"date":"2026-03-31","value":"0.92","vol":"0.65"},{"date":"2025-12-31","value":"4.38","vol":"2.59"},{"date":"2025-09-30","value":"3.10","vol":"1.94"}]
| 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|---|
| 存货增长 率(次) |
3.05 | 1.86 | 0.92 | 4.38 | 3.10 |
| 行业(次) | 1.93 | 1.30 | 0.65 | 2.59 | 1.94 |
该指标值越高，营运能力越强，行业排名越靠前。
现金流能力：数据暂时不全，请后续关注
[{"date":"2026-09-30","value":"15.49","vol":"-0.17"},{"date":"2026-06-30","value":"26.91","vol":"5.40"},{"date":"2026-03-31","value":"22.28","vol":"-2.46"},{"date":"2025-12-31","value":"36.49","vol":"15.68"},{"date":"2025-09-30","value":"3.04","vol":"4.82"}]
| 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|---|
| 现金流量净额/营业收入 | 15.49 | 26.91 | 22.28 | 36.49 | 3.04 |
| 行业 | -0.17 | 5.40 | -2.46 | 15.68 | 4.82 |
该指标值越高，现金流能力越强，行业排名越靠前。
[{"date":"2026-09-30","value":"","vol":"0.00"},{"date":"2026-06-30","value":"0.91","vol":"1.31"},{"date":"2026-03-31","value":"","vol":"0.00"},{"date":"2025-12-31","value":"1.17","vol":"1.59"},{"date":"2025-09-30","value":"","vol":"0.00"}]
| 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|---|
| 资本支出／折旧和摊销 | - | 0.91 | - | 1.17 | - |
| 行业 | 0.00 | 1.31 | 0.00 | 1.59 | 0.00 |
该指标值越低，现金流能力越强，行业排名越靠前。
短期偿债能力：很强，居行业前列，两项指标的行业排名分别为 12/217 ， 78/217。
[{"date":"2026-09-30","value":"1.93","vol":"3.64"},{"date":"2026-06-30","value":"1.53","vol":"3.68"},{"date":"2026-03-31","value":"2.02","vol":"3.65"},{"date":"2025-12-31","value":"1.81","vol":"3.44"},{"date":"2025-09-30","value":"1.76","vol":"3.52"}]
| 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|---|
| 流动比率 |
1.93 | 1.53 | 2.02 | 1.81 | 1.76 |
| 行业 | 3.64 | 3.68 | 3.65 | 3.44 | 3.52 |
该指标值越接近2，短期偿债能力越强，行业排名越靠前。
[{"date":"2026-09-30","value":"1.75","vol":"2.95"},{"date":"2026-06-30","value":"1.35","vol":"2.98"},{"date":"2026-03-31","value":"1.77","vol":"3.01"},{"date":"2025-12-31","value":"1.56","vol":"2.82"},{"date":"2025-09-30","value":"1.57","vol":"2.78"}]
| 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|---|
| 速动比率 |
1.75 | 1.35 | 1.77 | 1.56 | 1.57 |
| 行业 | 2.95 | 2.98 | 3.01 | 2.82 | 2.78 |
该指标值越接近1，短期偿债能力越强，行业排名越靠前。
长期偿债能力：尚可，接近行业平均，两项指标的行业排名分别为 57/217 ， 65/217。
[{"date":"2026-09-30","value":"33.92","vol":"32.63"},{"date":"2026-06-30","value":"38.89","vol":"33.24"},{"date":"2026-03-31","value":"36.78","vol":"32.97"},{"date":"2025-12-31","value":"38.84","vol":"34.15"},{"date":"2025-09-30","value":"41.43","vol":"33.59"}]
| 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|---|
| 资产负债 率(%) |
33.92 | 38.89 | 36.78 | 38.84 | 41.43 |
| 行业(%) | 32.63 | 33.24 | 32.97 | 34.15 | 33.59 |
该指标值越接近50%，长期偿债能力越强，行业排名越靠前。
[{"date":"2026-09-30","value":"0.51","vol":"0.66"},{"date":"2026-06-30","value":"0.64","vol":"0.70"},{"date":"2026-03-31","value":"0.58","vol":"9.64"},{"date":"2025-12-31","value":"0.63","vol":"1.73"},{"date":"2025-09-30","value":"0.71","vol":"1.17"}]
| 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|---|
| 产权比率 (%) |
0.51 | 0.64 | 0.58 | 0.63 | 0.71 |
| 行业(%) | 0.66 | 0.70 | 9.64 | 1.73 | 1.17 |
该指标值越高，长期偿债能力越强，行业排名越靠前。
机构评级
最近60个交易日，机构评级以买入为主，认为该股票非常值得关注。
| 研究机构 | 评级日期 | 最新评级 | 上次评级 |
| 国信证券 | 2026-11-05 | 买入 | |
| 华泰证券 | 2026-10-30 | 买入 | 买入 |
| 东吴证券 | 2026-10-30 | 买入 | 买入 |
| 广发证券 | 2026-10-29 | 买入 | 买入 |
| 中信建投证券 | 2026-10-29 | 买入 | 买入 |
| 兴业证券 | 2026-10-12 | 增持 |
机构预测
机构预测该股2026年每股收益与前一年相同，长期投资价值一般。
[{"date":"2022","yellowRectValue":"2.77","blueLineValue":"","type":""},{"date":"2023","yellowRectValue":"2.95","blueLineValue":"","type":""},{"date":"2024","yellowRectValue":"3.95","blueLineValue":"","type":""},{"date":"2025","yellowRectValue":"2.60","blueLineValue":"","type":""},{"date":"2026","yellowRectValue":"14.44","blueLineValue":"1.27","type":"YC"}]